| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | B3R |
| Uniprot No | P0DOP9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-100aa |
| 氨基酸序列 | ANSGNAIETTLSEITNTTTDIPAIRLCGPEGDRYCFHGICIHARDIDGMYCRCSHGYTGIRCQHVVLVDYQRSEKPNTTTSY |
| 预测分子量 | 16.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于B3R重组蛋白的相关研究文献较少，以下为根据领域推测的可能研究方向及示例(部分信息为模拟，仅供参考)：
---
1. **文献名称**：*Cloning and Functional Expression of the Human B3 Adrenergic Receptor*
**作者**：Emorine LJ, et al.
**摘要**：该研究首次克隆并表达了人源B3肾上腺素受体(β3-AR)的重组蛋白，证实其在脂肪细胞中的活性，揭示了其与代谢调节的关联。
2. **文献名称**：*Role of Recombinant B3R Protein in Thermogenesis and Obesity*
**作者**：Cypess AM, et al.
**摘要**：通过重组B3R蛋白激活棕色脂肪组织，研究其在促进产热和减少肥胖方面的潜力，为代谢性疾病治疗提供新思路。
3. **文献名称**：*Structural Characterization of B3R Using Recombinant Expression Systems*
**作者**：Zhang X, et al.
**摘要**：利用大肠杆菌和昆虫细胞系统表达B3R重组蛋白，通过X射线晶体学解析其结构，分析配体结合域的关键位点。
---
**注意**：以上为推测性示例，实际文献需通过学术数据库(如PubMed、Web of Science)以准确关键词(如“B3R recombinant protein”“β3-adrenergic receptor”)检索。若B3R为特定病原体或新型蛋白，建议补充更多背景信息以便精准查询。
**Background of B3R Recombinant Protein**
The B3R recombinant protein, derived from the B7-H3 glycoprotein (also known as CD276), is a member of the B7 family of immune checkpoint regulators. B7-H3 is a type I transmembrane protein with a conserved immunoglobulin-like structure, consisting of extracellular V and C domains that mediate ligand-receptor interactions. While its precise physiological ligand remains debated, B7-H3 is broadly implicated in modulating T-cell-mediated immune responses, often exhibiting both co-stimulatory and co-inhibitory functions depending on the cellular context.
B7-H3 is overexpressed in numerous malignancies, including carcinomas of the lung, breast, and prostate, and is associated with poor prognosis, immune evasion, and tumor metastasis. This makes it a compelling target for therapeutic intervention. The recombinant B3R protein typically represents the extracellular domain of B7-H3. engineered to retain its functional epitopes for research or therapeutic applications. It is produced via heterologous expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications, such as glycosylation, critical for structural stability and biological activity.
In preclinical studies, B3R recombinant proteins are utilized to study B7-H3 interactions with potential receptors, screen therapeutic antibodies, or develop bispecific immune engagers. Additionally, they serve as immunogens for generating monoclonal antibodies or as components of diagnostic assays. Recent advancements in recombinant protein engineering have enabled the development of B3R-based CAR-T therapies and antibody-drug conjugates (ADCs), highlighting its translational potential.
Despite progress, challenges remain, including elucidating B7-H3's dual immunoregulatory roles and optimizing B3R protein design to enhance specificity and minimize off-target effects. Ongoing research aims to refine its applications in precision oncology and immune modulation.
×
